NASDAQ$WBA

Walgreens Boots Alliance Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Walgreens reported a decrease in sales and adjusted EPS, impacted by opioid litigation and lower COVID-19 vaccine volumes, while raising full-year sales guidance.

Walgreens Boots Alliance reported first quarter fiscal 2023 results with sales decreasing 1.5 percent year-over-year to $33.4 billion. Adjusted EPS decreased 30.8 percent to $1.16. The company is maintaining full-year adjusted EPS guidance and raising full-year sales guidance.

  • First quarter loss per share was $4.31, compared to earnings per share of $4.13 in the year-ago quarter, reflecting a $6.5 billion pre-tax charge for opioid litigation.
  • Adjusted EPS decreased 30.8 percent to $1.16, down 29.9 percent on a constant currency basis.
  • First quarter sales decreased 1.5 percent year-over-year to $33.4 billion, up 1.1 percent on a constant currency basis.
  • Full-year adjusted EPS guidance maintained at $4.45 to $4.65; full-year sales guidance raised to $133.5 billion to $137.5 billion.

Headline financials

Total Revenue

$33.4B

Previous: $33.9B-1.5%
EPS (adj)

$1.16

Previous: $1.68-31.0%
Capital Expenditures

$610M

Previous: $454M+34.4%
Free Cash Flow

-$117M

Previous: $645M-118.1%
Net Income

-$3.72B

Previous: $3.53B-205.4%
Operating Income

-$6.15B

Previous: $1.3B-573.2%
Gross Profit

$6.95B

Previous: $7.58B-8.2%
Cash & Equivalents

$2.35B

Previous: $4.14B-43.2%
Total Assets

$92.9B

Previous: $96.5B-3.8%
Stock-Based Comp

$222M

Previous: $35M+534.3%

Revenue & EPS history

Walgreens · Revenue · Quarterly

$33.4B

Q1 2023-1.5%vs Q1 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Walgreens · $7.76B total across 2 segments · Q4 2023

  • International
    $5.78B
  • U.S. Healthcare
    $1.97B+217.0%

Forward guidance

Walgreens is maintaining its full-year adjusted EPS guidance of $4.45 to $4.65 and raising its full-year sales guidance to $133.5 billion to $137.5 billion.

Tailwinds

  • Strong core business growth
  • Summit Health acquisition
  • Refreshed currency rates
  • First quarter sales ahead of expectations
  • U.S. Healthcare targets raised with Summit Health announcement

Headwinds

  • Lapping fiscal year 2022 COVID-19 execution
  • Currency headwinds

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 16 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-0.1%

Avg return

Earnings day

+0.4%

Avg return

5 days after

-1.9%

Avg return

30 days after

53%

33 / 62 earnings

Positive

+29.1%

Q1 2025

Best reaction

-22.7%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025+0.4%+1.5%+2.7%
Q2 2025-1.1%+0.5%+4.1%
Q1 2025+29.1%+36.1%+10.0%
Q4 2024+23.0%+18.7%-2.0%
Q3 2024-22.7%-26.0%-24.5%
Q2 2024-7.0%-10.9%-15.7%
Q1 2024-2.2%-0.6%-11.4%
Q4 2023+2.9%+2.1%-7.3%
Q3 2023-7.9%-10.2%-3.0%
Q2 2023+3.7%+5.0%+6.6%
Q1 2023-2.3%-2.1%-1.1%
Q4 2022+4.1%+3.8%+29.4%
Q3 2022-5.7%-5.7%-2.9%
Q2 2022-7.6%-8.4%-10.6%
Q1 2022-0.3%+0.6%-10.0%
Q4 2021+3.5%+1.5%+4.8%
Q3 2021-8.4%
Q2 2021+3.3%
Q1 2021+5.1%
Q4 2020+4.2%
Q3 2020-5.1%
Q2 2020-5.4%
Q1 2020-7.8%
Q4 2019+1.5%
Q3 2019+4.4%
Q2 2019-13.6%
Q1 2019-8.2%
Q4 2018+1.6%
Q3 2018-9.4%
Q2 2018-0.7%
Q1 2018-3.4%
Q4 2017-0.3%
Q3 2017+1.6%
Q2 2017-1.0%
Q1 2017+0.1%
Q4 2016+5.7%
Q3 2016-3.6%
Q2 2016-3.0%
Q1 2016+1.8%
Q4 2015-11.9%
Q3 2015+8.4%
Q1 2014+4.9%
Q2 2015+4.9%
Q4 2013+4.9%
Q1 2015+3.2%
Q4 2014-0.9%
Q3 2014+0.6%
Q2 2014+1.0%
Q3 2013-1.0%
Q2 2013+0.4%
Q1 2013+1.6%
Q4 2012+1.4%
Q3 2012-3.2%
Q2 2012-1.9%
Q1 2012+4.1%
Q4 2011+0.4%
Q3 2011-0.9%
Q2 2011+1.8%
Q1 2010+2.5%
Q4 2010+1.8%
Q3 2010-0.1%
Q2 2009+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro